Bulls vs Bears
Click to unlock major analysts' bullish and bearish positions by joining Benzinga Edge.
$243.00
-4.16-1.68%
At close: -
$243.00
0.000.00%
After Hours: 4:00 PM EDT
Comments
Loading...
Bio-Rad Laboratories Analyst Ratings and Price Targets | NYSE:BIO | Benzinga
Bio-Rad Laboratories Inc has a consensus price target of $435.86 based on the ratings of 7 analysts. The high is $550 issued by Credit Suisse on August 4, 2023. The low is $315 issued by Jefferies on June 3, 2024. The 3 most-recent analyst ratings were released by Wells Fargo, RBC Capital, and RBC Capital on February 12, 2025, January 14, 2025, and December 9, 2024, respectively. With an average price target of $435.67 between Wells Fargo, RBC Capital, and RBC Capital, there's an implied 79.29% upside for Bio-Rad Laboratories Inc from these most-recent analyst ratings.
Analyst Firms Making Recommendations1
Wells Fargo
RBC Capital
Citigroup
Jefferies
UBS
1calculated from analyst ratings
Analyst Ratings for Bio-Rad Laboratories
| Buy Now | Get Alert | |||||||
|---|---|---|---|---|---|---|---|---|
| 02/12/2025 | Buy Now | 41.98% | Wells Fargo | Brandon Couillard70% | $360 → $345 | Maintains | Equal-Weight | Get Alert |
| 01/14/2025 | Buy Now | 97.94% | RBC Capital | Conor McNamara36% | $481 → $481 | Reiterates | Outperform → Outperform | Get Alert |
| 12/09/2024 | Buy Now | 97.94% | RBC Capital | Conor McNamara36% | $369 → $481 | Maintains | Outperform | Get Alert |
| 10/31/2024 | Buy Now | 85.19% | Citigroup | Patrick Donnelly80% | $400 → $450 | Maintains | Buy | Get Alert |
| 10/31/2024 | Buy Now | 93% | RBC Capital | Conor McNamara36% | $446 → $469 | Maintains | Outperform | Get Alert |
| 10/01/2024 | Buy Now | 64.61% | Citigroup | Patrick Donnelly80% | $350 → $400 | Upgrade | Neutral → Buy | Get Alert |
| 08/27/2024 | Buy Now | 39.92% | Wells Fargo | Brandon Couillard70% | → $340 | Initiates | → Equal-Weight | Get Alert |
| 08/16/2024 | Buy Now | 65.02% | RBC Capital | Conor McNamara36% | $401 → $401 | Reiterates | Outperform → Outperform | Get Alert |
| 08/02/2024 | Buy Now | 65.02% | RBC Capital | Conor McNamara36% | $402 → $401 | Maintains | Outperform | Get Alert |
| 08/02/2024 | Buy Now | 44.03% | Citigroup | Patrick Donnelly80% | $300 → $350 | Maintains | Neutral | Get Alert |
| 06/03/2024 | Buy Now | 29.63% | Jefferies | — | $440 → $315 | Assumes | Buy → Hold | Get Alert |
| 05/08/2024 | Buy Now | 58.44% | UBS | Dan Leonard55% | $420 → $385 | Maintains | Buy | Get Alert |
| 04/03/2024 | Buy Now | 50.21% | Citigroup | Patrick Donnelly80% | $400 → $365 | Downgrade | Buy → Neutral | Get Alert |
| 02/16/2024 | Buy Now | 72.84% | UBS | Dan Leonard55% | $395 → $420 | Maintains | Buy | Get Alert |
| 02/16/2024 | Buy Now | 97.53% | RBC Capital | Conor McNamara36% | $484 → $480 | Maintains | Outperform | Get Alert |
| 12/07/2023 | Buy Now | 62.55% | UBS | Dan Leonard55% | → $395 | Initiates | → Buy | Get Alert |
| 08/07/2023 | Buy Now | 116.05% | Wells Fargo | Dan Leonard55% | $550 → $525 | Maintains | Overweight | Get Alert |
| 08/04/2023 | Buy Now | 115.64% | RBC Capital | Conor McNamara36% | $522 → $524 | Maintains | Outperform | Get Alert |
| 08/04/2023 | Buy Now | 126.34% | Credit Suisse | Dan Leonard55% | $580 → $550 | Maintains | Outperform | Get Alert |
| 06/16/2023 | Buy Now | 126.34% | Wells Fargo | Dan Leonard55% | → $550 | Initiates | → Overweight | Get Alert |
| 05/08/2023 | Buy Now | 116.05% | Citigroup | Patrick Donnelly80% | $550 → $525 | Maintains | Buy | Get Alert |
| 05/08/2023 | Buy Now | 118.52% | RBC Capital | Conor McNamara36% | $582 → $531 | Maintains | Outperform | Get Alert |
| 05/05/2023 | Buy Now | 138.68% | Credit Suisse | Dan Leonard55% | $680 → $580 | Maintains | Outperform | Get Alert |
| 02/17/2023 | Buy Now | 138.27% | RBC Capital | Conor McNamara36% | $571 → $579 | Maintains | Outperform | Get Alert |
| 02/17/2023 | Buy Now | 179.84% | Credit Suisse | Dan Leonard55% | $640 → $680 | Maintains | Outperform | Get Alert |
| 12/07/2022 | Buy Now | 132.51% | RBC Capital | Conor McNamara36% | → $565 | Initiates | → Outperform | Get Alert |
| 10/28/2022 | Buy Now | 163.37% | Credit Suisse | Dan Leonard55% | $715 → $640 | Maintains | Outperform | Get Alert |
| 08/25/2022 | Buy Now | 194.24% | Credit Suisse | Dan Leonard55% | → $715 | Initiates | → Outperform | Get Alert |
| 07/08/2022 | Buy Now | 188.07% | Citigroup | Patrick Donnelly80% | $750 → $700 | Maintains | Buy | Get Alert |
FAQ
What is the target price for Bio-Rad Laboratories (BIO) stock?
The latest price target for Bio-Rad Laboratories (NYSE:BIO) was reported by Wells Fargo on February 12, 2025. The analyst firm set a price target for $345.00 expecting BIO to rise to within 12 months (a possible 41.98% upside). 13 analyst firms have reported ratings in the last year.
What is the most recent analyst rating for Bio-Rad Laboratories (BIO)?
The latest analyst rating for Bio-Rad Laboratories (NYSE:BIO) was provided by Wells Fargo, and Bio-Rad Laboratories maintained their equal-weight rating.
When was the last upgrade for Bio-Rad Laboratories (BIO)?
The last upgrade for Bio-Rad Laboratories Inc happened on October 1, 2024 when Citigroup raised their price target to $400. Citigroup previously had a neutral for Bio-Rad Laboratories Inc.
When was the last downgrade for Bio-Rad Laboratories (BIO)?
The last downgrade for Bio-Rad Laboratories Inc happened on April 3, 2024 when Citigroup changed their price target from $400 to $365 for Bio-Rad Laboratories Inc.
When is the next analyst rating going to be posted or updated for Bio-Rad Laboratories (BIO)?
Analysts arrive at stock ratings after doing extensive research, which includes going through public financial statements, talking to executives and customers of Bio-Rad Laboratories, and listening in to earnings conference calls. Most analysts do this every three months, so you should get 4 ratings per company per firm each year. The last rating for Bio-Rad Laboratories was filed on February 12, 2025 so you should expect the next rating to be made available sometime around February 12, 2026.
Is the Analyst Rating Bio-Rad Laboratories (BIO) correct?
While ratings are subjective and will change, the latest Bio-Rad Laboratories (BIO) rating was a maintained with a price target of $360.00 to $345.00. The current price Bio-Rad Laboratories (BIO) is trading at is $243.00, which is out of the analyst’s predicted range.
Browse analyst ratings and price targets on all stocks.